Microemulsions for oral administration and their therapeutic applications - Test2 - elhamkhani - TriplyDB

Microemulsions for oral administration and their therapeutic applications

Microemulsions for oral administration and their therapeutic applications

http://www.wikidata.org/entity/Q29307905

about

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Role of microemuslsions in advanced drug delivery.Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues Formulation and evaluation of microemulsion-based hydrogel for topical delivery.Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability Match of Solubility Parameters Between Oil and Surfactants as a Rational Approach for the Formulation of Microemulsion with a High Dispersed Volume of Copaiba Oil and Low Surfactant Content.

P2860

Q38082728-1B24FE1F-823E-449A-8448-7EB22116D28D Q38364835-1392AF3A-2CB4-4B02-98F8-5AC7D67C2F56 Q38820627-33691365-533C-4234-9225-4A1DB02AFD1F Q41834840-A7782BC5-9FFD-4526-8E26-2D0166864D2A Q41844266-A01089C7-2B9B-4EA3-A52E-8D4D21183D79 Q42291604-A38B1029-2699-4A03-B88A-2240A35FCF4D Q48252004-EB97ABA5-5B1F-4BCB-BBD6-86AA55F2D7B0

P2860

Microemulsions for oral administration and their therapeutic applications

http://www.wikidata.org/entity/Q29307905

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Microemulsions for oral administration and their therapeutic applications

@ast

Microemulsions for oral administration and their therapeutic applications

@en

type

label

Microemulsions for oral administration and their therapeutic applications

@ast

Microemulsions for oral administration and their therapeutic applications

@en

prefLabel

Microemulsions for oral administration and their therapeutic applications

@ast

Microemulsions for oral administration and their therapeutic applications

@en

P1433

Q29307905-FA907C33-C0F9-4C29-9DF8-41E6333D956C

P1476

Q29307905-1857533C-E161-4382-B2C1-3BA8BAA6FA4B

P2093

Q29307905-6A029271-952D-43EB-855C-37C4F4824489

P2860

Q29307905-015EA185-C121-4B82-8B56-5F7A5184B96D

Q29307905-018C558B-1901-407A-A883-6D6AB54514EC

Q29307905-01B59F8A-BB67-4D3B-957A-512474B5F943

Q29307905-0574EFBE-0786-4174-8980-F70820534C9D

Q29307905-07740B1E-542C-4688-A3F9-72320A11E850

Q29307905-0CE200E4-1C18-4F26-8348-56EF812BE792

Q29307905-10E47F96-549E-4596-BAFB-718E88E2C54D

Q29307905-20CF7705-31FC-4A72-8751-E1DA5E5FA739

Q29307905-21EF3D03-5C7D-4FA6-B321-153479D19721

Q29307905-23BACA94-E57B-4D02-A8D1-4C36DB8B6241

P304

Q29307905-88AA5F62-2132-45D7-8390-F437207D8344

P31

Q29307905-47BF5879-5163-457E-AE85-9850834658D8

P356

Q29307905-62EE3816-8977-4EB5-9059-2DFD4A920CB1

P407

Q29307905-42E35139-6501-4274-8C34-2EE993AFD10A

P433

Q29307905-DC74ADC5-8F0B-42CE-8FF3-CC0715D4B025

P478

Q29307905-04DA933A-9212-47CA-AB65-7C96D82698A7

P50

Q29307905-9E180FEB-6E94-4C1F-8D4D-48C75EF7E277

P577

Q29307905-C094FBD3-ED43-4F2B-B9F4-343B31584614

P5875

Q29307905-CAC9F2AD-4A3F-48CE-8A5C-7D2ED189DAE7

P698

Q29307905-CC0D837D-EEDA-499F-A595-D6EBC492F486

P356

17425247.2012.694865

P1433

Expert Opinion on Drug Delivery

P1476

Microemulsions for oral administration and their therapeutic applications

@en

P2093

David Attivi

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs.

Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.

Improving drug solubility for oral delivery using solid dispersions.

Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.

Risks and benefits of taxanes in breast and ovarian cancer.

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.

Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion.

P304

937-951

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425247.2012.694865

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Gibaud

P577

2012-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225183943

http://www.w3.org/2001/XMLSchema#string

P698

22663249

http://www.w3.org/2001/XMLSchema#string